guest ::
| Home > Articles > Published articles > Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes |
| Home > Articles > Published articles > Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes |
(Hospital Infantil Universitario Niño Jesús (Madrid)) (Centro de Investigación Biomédica en Red de Enfermedades Raras) (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) (Hospital Universitari Vall d'Hebron) (Banc de Sang i Teixits de Catalunya) (Institut de Recerca Pediàtrica Sant Joan de Déu) (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) (Hospital Universitari Vall d'Hebron) (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
| Date: | 2021 |
| Abstract: | Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21. 8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4. 27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1. 1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers. |
| Grants: | European Commission 305421 Ministerio de Sanidad, Servicios Sociales e Igualdad EC11/060 Ministerio de Sanidad, Servicios Sociales e Igualdad EC11/550 Ministerio de Economía y Competitividad SAF2015-68073-R Agencia Estatal de Investigación RTI2018-097125-B-I00 Agencia Estatal de Investigación RTI2018-098419-B-I00 Instituto de Salud Carlos III RD12/0019/0023 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Fanconi anemia ; HSPC collection ; Gene therapy ; Mozobil ; Mobilization ; Leukapheresis ; Plerixafor ; AMD3100 ; Lentiviral vector ; Filgrastim |
| Published in: | Molecular Therapy. Methods & Clinical Development, Vol. 22 (September 2021) , p. 66-75, ISSN 2329-0501 |
